Brief: Sygnis signs non-exclusive distribution agreement with Cambridge Bioscience Ltd
Brief: Sygnis FY 2014 operating loss reduced to 3.2 mln euros
Brief: Sygnis announces global launch of SunScript Reverse Transcriptase
Brief: Sygnis signs non-exclusive distribution agreement with Sopachem
Brief: Genetrix Life Sciences A.B. exempted from bidding for Sygnis AG
Brief: Sygnis signs distribution agreement for Trueprime products with Ozyme France
Brief: Sygnis signs non-exclusive distribution agreement for TruePrime family for Japanese market
Brief: Sygnis signs TruePrime Single Cell WGA Kit distribution agreement for North America
Brief: Sygnis AG signs distribution agreement with Bionova Cientifica
Brief: Sygnis AG launches its first proprietary product Trueprime Single Cell WGA Kit
Brief: Sygnis completes rights offering and private placement
Brief: Sygnis says TruePrime Single Cell WGA kit to be launched early 2015
Brief: Sygnis plans rights offering of up to 2.46 mln new shares
Brief: Sygnis says 9-month net loss of 2.4 mln euros, 17 pct better